J A Hank

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Paul M. Sondel, Peter Köhler, J A Hank et al. · PubMed · 1988 · 158 citations

Immunology, Recombinant Interleukin 2, Pathology +23

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

Jeff Sosman, Peter Köhler, J A Hank et al. · JNCI Journal of the National Cancer Institute · 1988 · 109 citations

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

J A Hank, Peter Köhler, G Weil-Hillman et al. · PubMed · 1988 · 81 citations

Immunology, Immune Regulation, Cell Death +20

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.

G Weil-Hillman, Stephan D. Voss, Paul Fisch et al. · PubMed · 1990 · 30 citations

Innate Immune System, Immunology, Immune Regulation +22

Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.

J A Hank, Jean E. Surfus, J. Gan et al. · PubMed · 1999 · 28 citations

Clinical Immunology, Laboratory Immunology, Immunodeficiencies +20